Helmedix Pty, a biotech spin out using technology first developed at the University of Technology, Sydney’s biotech research unit ithree institute, has launched with a $1.29m investment from Australia’s Medical Research Commercialisation Fund (MRCF). The Australia-based spin-out will use the funding to develop therapeutic peptide drugs for preventing and treating immunological diseases which currently affect…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
